Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1Phase 1 1

Status

Completed 73Recruiting 61Not yet recruiting 21Unknown 15Terminated 15Active not recruiting 15Withdrawn 5Enrolling by invitation 3

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5Observational 2

Sponsor

Conditions

Breast Neoplasms 370Neoplasms 253Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 192Lung Neoplasms 142Colorectal Neoplasms 139Neoplasm Metastasis 132Pancreatic Neoplasms 131Leukemia, Myeloid, Acute 126Multiple Myeloma 123Lymphoma 115Carcinoma, Hepatocellular 111Ovarian Neoplasms 98Melanoma 97Recurrence 93Leukemia 89Head and Neck Neoplasms 89Leukemia, Lymphocytic, Chronic, B-Cell 86Brain Neoplasms 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Glioblastoma 77Lymphoma, Non-Hodgkin 73Squamous Cell Carcinoma of Head and Neck 71Lymphoma, Follicular 70Lymphoma, Large B-Cell, Diffuse 66Colonic Neoplasms 66Carcinoma, Renal Cell 62Hematologic Neoplasms 59Sarcoma 55Glioma 53

Interventions

Oxaloacetic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Myasthenia Gravis × Clear all
NCT04965987 2025-07-11

Oxaloacetate in Myasthenia Gravis

University of Kansas Medical Center

Phase 1 Withdrawn

Myasthenia Gravis

NCT06419166 2025-06-27

gMG

Zhejiang University

Phase EARLY_PHASE1 Withdrawn

Myasthenia Gravis

NCT04982289 2022-02-11

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 2 Withdrawn

Myasthenia Gravis

NCT03900585 2021-03-10

Can Interval Walking Influence on Fatigue in the Danish Cohort of Myasthenia Gravis Patients

Rigshospitalet, Denmark

Phase NA Withdrawn

Myasthenia Gravis

NCT03165435 2018-05-30

A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis

CuraVac

Phase 2/3 Withdrawn

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡